MedTrace Logo

Magnesium-L-Threonate Improves Menopausal Symptoms

NCT06959745 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2025-05-07

No results posted yet for this study

Summary

This trial has a randomized, single-blind, single-center, parallel-controlled design, with participant screening and trial implementation conducted at Guangdong Provincial People's Hospital. The study evaluate the efficacy of oral magnesium L-threonate supplementation on improving menopausal symptoms and quality of life among peri/post-menopausal women.

This trial aims to explore whether oral magnesium L-threonate supplementation could alleviate menopausal syndromes.

Participants will randomly assigned to conduct oral magnesium L-threonate supplementation or placebo for 8 weeks. Face-to-face and internet follow up will be conducted once per 2 weeks.

Conditions

  • Menopause Syndrome
  • Magnesium

Interventions

DRUG

Magnesium-L-Threonate

Magnesium L-threonate, 1740 mg, taken orally, twice a day, for 8 weeks.

DRUG

Placebo

Placebo, 1740 mg, taken orally, twice a day, for 8 weeks.

Sponsors & Collaborators

  • Guangdong Provincial People's Hospital

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
60 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-05-15
Primary Completion
2025-09-30
Completion
2025-12-30

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06959745 on ClinicalTrials.gov